Peter Marks, head of the FDA’s Center for Biologics Evaluation and Research, said there was “significant concern” as the disease has spread to “six continents” overnight.(Read more) Shares of NV5 Global, Inc. NVEE declined 1.8% after the company lagged the Zacks Consensus Estimates in both earnings and revenues for the quarter ended December 2019.